Having excellent care and support (and even an infusion center) right here in my neighborhood gives me a sense of security and well-being, and I can trace that support directly back to the IPPF, who helped me find the way. Thank you, IPPF!PemPress & PemPress Education)
Just spending time [at the Patient Education Conference] with people who knew exactly what I was going through, who knew the instantaneous fear and rage that goes along with each new lesion, who were discovering how to find the shady spots at high noon, was an amazing comfort.PemPress & PemPress Education)
I had never told anyone except my close family that I had an autoimmune disease. I hid it away like a dirty secret because I was afraid of appearing weak or being treated differently. Especially as a student of medicine—we are supposed to treat patients, not be them.PemPress & PemPress Education)
I remember what it was like for me when I was first diagnosed with PV, so I can empathize with the patients who contact the IPPF.PemPress & PemPress Education)
Genentech announced this week that positive top line results from the Roche-sponsored Phase III PEMPHIX study evaluating the efficacy and safety of Rituxan® (rituximab) compared to mycophenolate mofetil (MMF) in adults with moderate to severe pemphigus vulgarisPemPress & PemPress Education)
The U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to bertilimumab for the treatment of bullous pemphigoid.PemPress & PemPress Education)
On Thursday, June 7th, the FDA approved Rituxan for the treatment of adults with moderate to severe pemphigus vulgaris (PV). Rituxan is the first biologic therapy approved by the FDA for PV and the first major advancement in the treatment of PV in more than 60 years.
Syntimmune Announces Positive Preliminary Results from Clinical Proof-of-Concept Trial of SYNT001 in Pemphigus Vulgaris and Foliaceus19 May 2018 (PemPress & PemPress Education)
Syntimmune recently announced positive preliminary results from its phase 1b proof-of-concept trial of SYNT001 in pemphigus vulgaris and foliaceus patients. It’s exciting for the IPPF to share good news related to research and treatments. The full press release from Syntimmune can be found here. The following is an excerpt: Syntimmune, Inc., a clinical-stage biotechnology company developing antibody therapeutics targeting…PemPress & PemPress Education)
Genentech recently announced an important FDA decision that could potentially impact future treatment options for pemphigus. Here at the IPPF, it’s especially exciting when we get to share good news related to research and treatments. The full press release from Genentech can be found here. The following is an excerpt: The U.S. Food and Drug Administration (FDA) has accepted Genentech’s Supplemental…PemPress & PemPress Foundation)
We had a great 2017 with your help!